Soligenix, Inc.
SNGXHealthcare|Biotechnology|US
$0.34
+0.00 (+0.51%)
DCF Value
$1.27
Tangible Book / Share
$0.39
Cash / Share
$0.57
Analyst Consensus
Buy8 analysts
Strong Buy
0
Buy
5
Hold
3
Sell
0
Strong Sell
0
Rating Trend
Dec 25
1 buy · 0 hold · 0 sell
Jan 26
1 buy · 0 hold · 0 sell
Feb 26
1 buy · 0 hold · 0 sell
Mar 26
1 buy · 0 hold · 0 sell
Apr 26
1 buy · 0 hold · 0 sell
May 26
1 buy · 0 hold · 0 sell
Jun 26
1 buy · 0 hold · 0 sell
Jul 26
1 buy · 0 hold · 0 sell
Aug 26
1 buy · 0 hold · 0 sell
Sep 26
1 buy · 0 hold · 0 sell
Oct 26
1 buy · 0 hold · 0 sell
Nov 26
1 buy · 0 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Alliance Global Partners | maintain | Buy | Jul 16, 2025 |
| B. Riley Securities | maintain | Buy | Dec 4, 2020 |
| B. Riley FBR | maintain | Buy | Dec 4, 2020 |
| Dawson James | downgrade | Buy →Neutral | Jul 28, 2020 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jan 31, 2018 |
| H.C. Wainwright | downgrade | Buy →Neutral | Jan 31, 2018 |
| Maxim Group | maintain | Buy | Aug 14, 2017 |
| H.C. Wainwright | maintain | Buy | Jul 17, 2017 |
| Aegis Capital | maintain | Buy | Sep 7, 2016 |
Earnings History
Next report: Mar 30, 2027 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.05 | $-0.10 | — | — |
| Aug 7, 2026 | $-0.12 | $-0.15 | — | — |
| May 8, 2026 | $-0.28 | $-0.30 | — | — |
| Apr 3, 2026 | $0.32 | $-0.27 | — | — |
| Nov 7, 2025 | $-0.58 | $-0.63 | — | — |
| Aug 14, 2025 | $-0.82 | $-0.79 | — | — |
| May 9, 2025 | $-1.06 | $-0.67 | — | — |
| Mar 21, 2025 | $-1.14 | $-0.95 | $6.4K | $200.0K |
News
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended September 30, 2026.
Nov 6, 2026prnewswire.com
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's
Aug 27, 2026defenseworld.net